September 9, 2009

Pluristem Studies Stem Cell Product to Treat CLI

September 10, 2009—Pluristem Therapeutics Inc. (Haifa, Israel) announced the commencement of enrollment in the United States for a phase 1 clinical trial with its unmatched placenta-derived stem cell product, PLX-PAD (Placental Expanded–Peripheral Arterial Disease) as a candidate for the treatment of critical limb ischemia (CLI). Patients are being enrolled at the Center for Therapeutic Angiogenesis in Birmingham, Alabama, and Duke University Medical Center. The initiation of this study comes after the US Food and Drug Administration approval of the company's investigational new drug application to begin clinical trials with PLX-PAD. The phase 1 study is designed to evaluate the safety of PLX-PAD in patients with CLI. Up to 12 adults with the disease will be included in this dose escalating trial. PLX-PAD is a placental-derived, mesenchymal-like stromal cell product, the company stated.

Subscribe to our weekly newsletter.

Stay informed on the week's top stories including literature summaries, device approvals, guideline changes, and more. Plus, get our latest issues & supplements delivered to your inbox each month.

September 9, 2009

Pluristem Studies Stem Cell Product to Treat CLI

Current Issue

Keep In Touch